Keros Therapeutics (NASDAQ:KROS) Receives “Buy” Rating from Guggenheim

Guggenheim restated their buy rating on shares of Keros Therapeutics (NASDAQ:KROS) in a report issued on Wednesday morning,Benzinga reports.

A number of other research analysts also recently issued reports on KROS. Wedbush restated an “outperform” rating and set a $84.00 target price on shares of Keros Therapeutics in a research report on Thursday, November 7th. Scotiabank assumed coverage on shares of Keros Therapeutics in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $77.00 price objective for the company. Bank of America decreased their price objective on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research report on Thursday, September 12th. Jefferies Financial Group assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They issued a “buy” rating for the company. Finally, HC Wainwright reiterated a “buy” rating and issued a $100.00 price objective on shares of Keros Therapeutics in a research report on Thursday, November 7th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Keros Therapeutics currently has an average rating of “Buy” and an average price target of $88.89.

Keros Therapeutics Price Performance

Shares of KROS opened at $67.79 on Wednesday. The firm has a market capitalization of $2.75 billion, a PE ratio of -13.01 and a beta of 1.20. Keros Therapeutics has a 1-year low of $27.31 and a 1-year high of $73.00. The company’s fifty day moving average price is $59.89 and its 200-day moving average price is $52.48.

Keros Therapeutics (NASDAQ:KROS) last posted its earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. Keros Therapeutics’s revenue for the quarter was up 4750.0% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.33) EPS. As a group, research analysts anticipate that Keros Therapeutics will post -5.28 EPS for the current fiscal year.

Institutional Trading of Keros Therapeutics

Several large investors have recently bought and sold shares of KROS. California State Teachers Retirement System grew its stake in Keros Therapeutics by 14.0% during the 1st quarter. California State Teachers Retirement System now owns 25,314 shares of the company’s stock valued at $1,676,000 after acquiring an additional 3,111 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Keros Therapeutics during the 2nd quarter valued at about $532,000. Assenagon Asset Management S.A. purchased a new stake in Keros Therapeutics during the 2nd quarter valued at about $1,118,000. Bank of New York Mellon Corp grew its stake in Keros Therapeutics by 18.8% during the 2nd quarter. Bank of New York Mellon Corp now owns 118,388 shares of the company’s stock valued at $5,410,000 after acquiring an additional 18,755 shares in the last quarter. Finally, Rhumbline Advisers grew its stake in Keros Therapeutics by 20.6% during the 2nd quarter. Rhumbline Advisers now owns 41,638 shares of the company’s stock valued at $1,903,000 after acquiring an additional 7,111 shares in the last quarter. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.